Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effect of Toothpaste on the Reduction of Plaque and Inflammation

5 de fevereiro de 2016 atualizado por: Katrin Lorenz, Technische Universität Dresden

Clinical Evaluation of the Effect of an Experimental Toothpaste on the Reduction of Dental Plaque and Gingival Inflammation

The purpose of this double blind study is to prove whether a fluoride containing toothpaste is able to reduce dental plaque and gingival inflammation in patients who have gingivitis when applied twice daily during brushing at home over a period of 12 weeks.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

Before study start, investigators and study nurses will be trained on how to apply SOPs, parameters, and adverse event management. On-site monitoring will be done by the sponsor after recruitment, after visit 2 and after the final visit.

All source data will be entered in paper CRFs. For the statistical analysis these data will be entered into the data bank via double data entry. Programmed range checks, validity checks, consistency checks, and manual/visual data checks for medicinal plausibility will be done before the blind data review meeting. During blind data review meeting minor protocol violations will be recorded and assessed. No imputation of missing data will be done for ITT or PP analyses.

The sample size estimation was carried out by means of one-sided unpaired t-test with a one-sided significance level of α=0.05. For testing superiority of the test product over negative control, the investigators test the hypothesis, H0: μTest product - μNegative control ≤ 0 H1: μTest product - μNegative control > 0 by using a one-sided t-test with α=0.05. A relevant difference of Δ=0.14 and a standard deviation of σ=0.4 was assumed based on previous studies. When estimating a drop-out rate of about 20 % a total of 120 = 102 + 18 subjects per group will be assigned at study start. Drop-outs will not be replaced during the study.

The primary parameter is the difference of plaque index between baseline (V1) value and the value after 12 weeks +/- 5 days (V3) of product use. For primary statistical analysis, a t-tests (unpaired situation) will be performed at a one-sided significance level of α=0.05. The primary efficacy analysis will be performed on the ITT-analysis set.

Secondary variables will be assessed with t-tests and confidence intervals to compare differences between V2, V3, and baseline for test product group and negative control group. Descriptive statistics will be performed for oral examinations for each group (counts and percentages of scores for nominal and ordinal scaled data, for at least ordinal scaled data minimum, maximum, median, mean value and standard deviation).

A two-sided significance level of α=0.05 is chosen for all secondary analyses, no adjustment for multiplicity will be done. Safety assessments will be based mainly on the frequency of adverse events.

Tipo de estudo

Intervencional

Inscrição (Real)

241

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Alemanha
      • Dresden, Alemanha, 01307
        • Technische Universität Dresden

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Male and female adults (aged 18 to 65 years),
  • Individuals with gingival inflammation, mean full-mouth GI ≥ 1.2 at inclusion,
  • Individuals with plaque, mean full-mouth PI ≥ 1.2 at inclusion,
  • Non-smokers or former smokers for at least 1 year or occasional smokers with a maximum of 5 cigarettes per week,
  • Individuals who have at least 20 own teeth excluding the wisdom teeth,
  • Subjects must have read, understood and signed the informed consent form
  • Willingness to abstain from use of interdental brushing devices that contain antibacterial agents, like amine fluoride, chlorhexidine, silver ions etc. during the full course of the study

Exclusion Criteria:

  • Individuals who have severe systemic diseases (tumors, infectious diseases) and diseases that require regular systemic medication intake that may affect the gingival condition (e. g. phenytoin, nifedipine, cyclosporine, antibiotics, steroids, antiphlogistics)
  • Individuals who have moderate and severe chronic or aggressive periodontitis (PSI > 2 in more than 2 sextants or PSI > 3),
  • Individuals who require antibiotic treatments for dental appointments (endocarditis prophylaxis), Individuals treated with antibiotics less than 8 weeks prior to the baseline examination and/or during the duration of the trial,
  • Individuals who have participated in another clinical study less than 4 weeks prior to the baseline examination,
  • Individuals who have mucosal diseases,
  • Individuals who have severe oro-pharyngeal infections,
  • Individuals who have significant dental disorders (e.g.: caries, suspected pulp pathology, abscess, pulpitis),
  • History of gingival surgery in the previous three month,
  • Ongoing dental treatment or any other medical treatment of the oral cavity,
  • Individuals who are pregnant or breast feeding,
  • Individuals with a history of chronic drug abuse or another illness which does not allow the person to assess the nature and/or possible consequences of the study,
  • Smokers with more than 5 cigarettes per week,
  • Individuals with known hypersensitivity or allergy to the test products and its ingredients,
  • Individuals who were treated with antibacterial mouthrinses (e. g. chlorhexidine) 4 weeks or less before recruitment,
  • Individuals unwilling to abstain from additional oral hygiene measures during the treatment phase with exception of their habitual mechanical cleaning procedures,
  • Non-Caucasians,
  • Subjects can be excluded at the principal investigators discretion.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Test group
Amine fluoride toothpaste
Outro: Amine fluoride
toothpaste
Comparador de Placebo: Control group
Placebo Sodium monofluorophosphate toothpaste
Outro: Placebo
toothpaste
Outros nomes:
  • Sodium monofluorophosphate

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Plaque index (Silness and Loe 1964)
Prazo: Change in plaque index from baseline at 12 weeks
Difference of plaque index, compared between test group and control group.
Change in plaque index from baseline at 12 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Plaque index (Silness and Loe 1964)
Prazo: Change in plaque index from baseline at 3 weeks
Difference of plaque index, compared between test group and control group.
Change in plaque index from baseline at 3 weeks
Plaque index (Silness and Loe 1964)
Prazo: Change in plaque index from week 3 at 12 weeks
Difference of plaque index, compared between test group and control group.
Change in plaque index from week 3 at 12 weeks
Gingival Index (Loe 1967)
Prazo: Change in gingival index from baseline at 3 weeks
Difference of gingival index, compared between test group and control group.
Change in gingival index from baseline at 3 weeks
Gingival Index (Loe 1967)
Prazo: Change in gingival index from baseline at 12 weeks
Difference of gingival index, compared between test group and control group.
Change in gingival index from baseline at 12 weeks
Gingival Index (Loe 1967)
Prazo: Change in gingival index from 3 weeks at week 12
Difference of gingival index, compared between test group and control group.
Change in gingival index from 3 weeks at week 12
Modified Sulcus Bleeding Index (Muhlemann and Son 1971):
Prazo: Change in bleeding index from baseline at 12 weeks
Difference of bleeding index, compared between test group and control group.
Change in bleeding index from baseline at 12 weeks
Modified Sulcus Bleeding Index (Muhlemann and Son 1971):
Prazo: Change in bleeding index from baseline at week 3
Difference of bleeding index, compared between test group and control group.
Change in bleeding index from baseline at week 3
Modified Sulcus Bleeding Index (Muhlemann and Son 1971):
Prazo: Change in bleeding index from week 3 at week 12
Difference of bleeding index, compared between test group and control group.
Change in bleeding index from week 3 at week 12
Adverse events
Prazo: up to 12 weeks from baseline
List all
up to 12 weeks from baseline

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Technische Universität Dresden

Colaboradores

Colgate Palmolive

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de setembro de 2015

Conclusão Primária (Real)

1 de fevereiro de 2016

Conclusão do estudo (Real)

1 de fevereiro de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

3 de setembro de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de setembro de 2015

Primeira postagem (Estimativa)

17 de setembro de 2015

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

8 de fevereiro de 2016

Última atualização enviada que atendeu aos critérios de controle de qualidade

5 de fevereiro de 2016

Última verificação

1 de fevereiro de 2016

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • PAR012015

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever